Deep Sleep and Alpha Synuclein; Depression’s Link to Alzheimer’s; EEG, EMG Training

Deep sleep accelerated alpha-synuclein removal in mouse models of Parkinson’s disease. (Science Translational Medicine)

Skin denervation may be a progression marker for Parkinson’s. (NPJ Parkinson’s Disease)

A Mendelian randomization analysis suggested depression may have a causal role in Alzheimer’s disease, but not the reverse. (Biological Psychiatry)

Medicare’s preliminary decision about whether to pay for the controversial Alzheimer’s treatment aducanumab (Aduhelm) is due this month; the drug still faces global criticism and hurdles. (New York Times)

President Joe Biden signed the Accelerating Access to Critical Therapies for ALS Act, authorizing $100 million annually for the next 5 years to help patients with ALS and other terminal diseases have access to to promising therapies. (CNN)

Nearly 3% of people with traumatic brain injury reported post-traumatic epilepsy a year later. (JAMA Network Open)

Repetitive head impacts in youth tackle football were not consistently linked to cognitive and behavioral problems. (JAMA Network Open)

A study in England showed the risk of SARS-CoV-2 infection was higher in MS patients on ocrelizumab (Ocrevus) or fingolimod (Gilenya) than in the general population. (Multiple Sclerosis and Related Disorders)

Parkinson’s disease was more common in states with more underground lead pipes. (Clinical Parkinsonism and Related Disorders)

P2B001, a novel combination of extended release formulations of pramipexole (Mirapex) and rasagiline (Azilect), showed superior efficacy compared with its individual components in a phase III study of early Parkinson’s disease, Pharma Two B said.

Only 37% of graduating neurology residents are confident performing and interpreting electroencephalography; 23% in electromyography. How should training change? (JAMA Neurology)